Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NYSE:INSP NASDAQ:NVCR NYSE:STVN NASDAQ:SWAV On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeINSPInspire Medical Systems$133.64+5.3%$140.52$123.00▼$225.00$3.74B1.25554,235 shs968,027 shsNVCRNovoCure$17.51+3.7%$17.65$14.17▼$34.13$1.88B0.721.13 million shs1.36 million shsSTVNStevanato Group€25.03+2.8%€23.45€17.12▼€25.88€7.58B0.55335,617 shs241,100 shsSWAVShockwave Medical$334.75$332.85$157.00▼$334.90$12.57B0.88968,088 shsN/AElon Musk's Next MoveExplore Elon Musk’s boldest ventures yet—from AI and autonomy to space colonization—and find out how investors can ride the next wave of innovation.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceINSPInspire Medical Systems-0.99%-1.68%-6.37%-10.25%-9.77%NVCRNovoCure-4.60%-5.11%-0.65%+9.89%+0.66%STVNStevanato Group-1.46%-1.14%+1.81%+30.13%+30.76%SWAVShockwave Medical0.00%0.00%0.00%0.00%0.00%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationINSPInspire Medical Systems4.8272 of 5 stars4.41.00.04.83.02.51.9NVCRNovoCure3.5767 of 5 stars3.41.00.04.51.91.70.0STVNStevanato GroupN/AN/AN/AN/AN/AN/AN/AN/ASWAVShockwave MedicalN/AN/AN/AN/AN/AN/AN/AN/ACompare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceINSPInspire Medical Systems 2.73Moderate Buy$211.9158.57% UpsideNVCRNovoCure 2.71Moderate Buy$32.4385.20% UpsideSTVNStevanato Group 2.86Moderate BuyN/AN/ASWAVShockwave Medical 0.00N/AN/AN/ACurrent Analyst Ratings BreakdownLatest SWAV, STVN, INSP, and NVCR Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails7/8/2025NVCRNovoCureLADENBURG THALM/SH SHSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.006/30/2025STVNStevanato GroupWilliam BlairSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOutperform6/27/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$34.005/6/2025INSPInspire Medical SystemsMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$220.00 ➝ $200.005/6/2025INSPInspire Medical SystemsJPMorgan Chase & Co.Subscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$235.00 ➝ $195.005/6/2025INSPInspire Medical SystemsWells Fargo & CompanySubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetEqual Weight ➝ Equal Weight$195.00 ➝ $174.005/6/2025INSPInspire Medical SystemsRobert W. BairdSubscribe to MarketBeat All Access for the recommendation accuracy ratingBoost Price TargetOutperform ➝ Outperform$230.00 ➝ $236.004/23/2025NVCRNovoCurePiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$42.00 ➝ $34.004/21/2025INSPInspire Medical SystemsStifel NicolausSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$190.00 ➝ $175.004/21/2025INSPInspire Medical SystemsKeyCorpSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetOverweight ➝ Overweight$234.00 ➝ $216.004/21/2025STVNStevanato GroupStephensSubscribe to MarketBeat All Access for the recommendation accuracy ratingUpgradeStrong-Buy(Data available from 7/8/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookINSPInspire Medical Systems$802.80M4.91$1.80 per share74.28$23.01 per share5.81NVCRNovoCure$605.22M3.23N/AN/A$3.33 per share5.26STVNStevanato Group€1.19B6.34€0.78 per share32.26€5.02 per share4.99SWAVShockwave Medical$787.97M15.95$4.31 per share77.61$20.02 per share16.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateINSPInspire Medical Systems$53.51M$2.1761.5941.501.947.92%10.00%8.68%8/5/2025 (Estimated)NVCRNovoCure-$168.63M-$1.51N/AN/AN/A-26.41%-45.46%-13.34%7/24/2025 (Estimated)STVNStevanato Group€127.45M€0.5149.0843.162.3311.14%10.00%6.03%N/ASWAVShockwave Medical$147.28M$4.2878.2154.342.4320.75%24.79%11.95%N/ALatest SWAV, STVN, INSP, and NVCR EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails8/5/2025Q2 2025INSPInspire Medical Systems$0.22N/AN/AN/A$214.50 millionN/A7/24/2025Q2 2025NVCRNovoCure-$0.40N/AN/AN/A$153.87 millionN/A5/5/2025Q1 2025INSPInspire Medical Systems-$0.23$0.10+$0.33$0.10$194.89 million$201.32 million4/24/2025Q1 2025NVCRNovoCure-$0.47-$0.31+$0.16-$0.31$147.57 million$154.99 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthINSPInspire Medical SystemsN/AN/AN/AN/AN/ANVCRNovoCureN/AN/AN/AN/AN/ASTVNStevanato GroupN/AN/AN/AN/A1 YearsSWAVShockwave MedicalN/AN/AN/AN/AN/ALatest SWAV, STVN, INSP, and NVCR DividendsAnnouncementCompanyPeriodAmountYieldEx-Dividend DateRecord DatePayable Date5/2/2025STVNStevanato Groupannual€0.060.3%6/5/20256/5/20257/17/2025(Data available from 1/1/2013 forward)Compare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioINSPInspire Medical SystemsN/A9.017.44NVCRNovoCure0.271.471.41STVNStevanato Group0.221.831.26SWAVShockwave Medical0.9713.8112.61Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipINSPInspire Medical Systems94.91%NVCRNovoCure84.61%STVNStevanato GroupN/ASWAVShockwave Medical95.35%Insider OwnershipCompanyInsider OwnershipINSPInspire Medical Systems2.30%NVCRNovoCure5.52%STVNStevanato GroupN/ASWAVShockwave Medical3.40%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableINSPInspire Medical Systems1,24629.49 million28.82 millionOptionableNVCRNovoCure1,488111.49 million105.33 millionOptionableSTVNStevanato Group5,521302.84 millionN/AOptionableSWAVShockwave Medical1,46837.54 million36.27 millionOptionableSWAV, STVN, INSP, and NVCR HeadlinesRecent News About These CompaniesShockwave Medical unveil Forward Intravascular Lithotripsy Platform in USMarch 6, 2025 | medicaldialogues.inMShockwave Medical Launches Novel Forward Intravascular Lithotripsy Platform in U.S. to Transform Treatment of Difficult-to-Cross Calcified LesionsMarch 4, 2025 | finance.yahoo.comShockwave Medical’s Javelin IVL catheter meets primary trial endpointsNovember 5, 2024 | massdevice.comShockwave Medical concludes enrollment in all-female coronary IVL studyNovember 2, 2024 | medicaldialogues.inMShockwave completes enrollment in all-female cardiovascular trialOctober 30, 2024 | bioworld.comBShockwave Medical completes enrollment in all-female IVL studyOctober 29, 2024 | massdevice.comMicro-shockwave electronic therapy shows potential for safe non-invasive treatment of brain disordersOctober 28, 2024 | medicalxpress.comMMayo Clinic Q&A: Shockwave therapy may help relieve foot problemOctober 27, 2024 | postbulletin.comPJohnson & Johnson completes $1.7B V-Wave acquisitionOctober 9, 2024 | massdevice.comNew shockwave therapy offers hope for chronic pain sufferersSeptember 25, 2024 | local12.comLShockwave E8: Extend Your Capabilities With the New Peripheral IVL WorkhorseSeptember 24, 2024 | evtoday.comEShockwave E8 Peripheral IVL Catheter LaunchedSeptember 17, 2024 | evtoday.comESmiths Medical recalls airway tubes over defect linked to more than 10 injuriesSeptember 17, 2024 | medtechdive.comMJ&J’s Shockwave adds enhanced catheter to U.S. IVL portfolioSeptember 17, 2024 | massdevice.comJ&J’s Shockwave strengths IVL grasp with new US catheter launchSeptember 17, 2024 | msn.comNew noninvasive technique provides effective treatment for urinary stonesSeptember 12, 2024 | msn.comBalancing Growth and Challenges: A Hold Rating for Johnson & Johnson’s Medtech Division Amidst China HeadwindsSeptember 6, 2024 | markets.businessinsider.comSeptember 2024 edition: The Medtech Big 100, PFA catheters and Shockwave’s ReducerAugust 30, 2024 | medicaldesignandoutsourcing.comMBaird Q2 2024 Small/Mid Cap Growth Equity Fund CommentaryAugust 22, 2024 | seekingalpha.comIntroducing OMNIWave(TM): Revolutionizing Treatment with Advanced Shockwave Technology and Comprehensive Business SolutionsAugust 15, 2024 | markets.businessinsider.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesWhy BigBear.ai Could Rally 100% and Catch Palantir SoonBy Gabriel Osorio-Mazilli | June 30, 2025View Why BigBear.ai Could Rally 100% and Catch Palantir Soon3 Defense Leaders Set to Gain From Rising Military SpendBy Chris Markoch | July 5, 2025View 3 Defense Leaders Set to Gain From Rising Military SpendIPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBy Dan Schmidt | June 20, 2025View IPO Momentum Returns: 3 Stocks Rising After CoreWeave’s SurgeBigBear.ai Poised to Benefit as Palantir Dominates AI DefenseBy Gabriel Osorio-Mazilli | June 23, 2025View BigBear.ai Poised to Benefit as Palantir Dominates AI Defense330% Returns YTD: Is CoreWeave's Momentum Softening?By Nathan Reiff | June 18, 2025View 330% Returns YTD: Is CoreWeave's Momentum Softening?SWAV, STVN, INSP, and NVCR Company DescriptionsInspire Medical Systems NYSE:INSP$133.64 +6.73 (+5.30%) Closing price 03:59 PM EasternExtended Trading$133.47 -0.17 (-0.13%) As of 06:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Inspire Medical Systems, Inc., a medical technology company, focuses on the development and commercialization of minimally invasive solutions for patients with obstructive sleep apnea (OSA) in the United States and internationally. The company offers Inspire system, a neurostimulation technology that provides a safe and effective treatment for moderate to severe OSA. It also develops a novel, closed-loop solution that continuously monitors a patient's breathing and delivers mild hypoglossal nerve stimulation to maintain an open airway. The company was incorporated in 2007 and is headquartered in Golden Valley, Minnesota.NovoCure NASDAQ:NVCR$17.51 +0.62 (+3.67%) Closing price 04:00 PM EasternExtended Trading$17.66 +0.15 (+0.86%) As of 06:17 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.NovoCure Limited, an oncology company, engages in the development, manufacture, and commercialization of tumor treating fields (TTFields) devices for the treatment of solid tumor cancers in the United States, Germany, Japan, Greater China, and internationally. The company's TTFields devices include Optune Gio and Optune Lua. It also has ongoing clinical trials investigating TTFields in brain metastases, gastric cancer, glioblastoma, liver cancer, non-small cell lung cancer, pancreatic cancer, and ovarian cancer. NovoCure Limited was incorporated in 2000 and is headquartered in Saint Helier, Jersey.Stevanato Group NYSE:STVN€25.03 +0.68 (+2.79%) As of 03:59 PM EasternStevanato Group S.p.A. engages in the design, production, and distribution of products and processes to provide integrated solutions for bio-pharma and healthcare industries in Europe, the Middle East, Africa, North America, South America, and the Asia Pacific. The company operates in two segments, Biopharmaceutical and Diagnostic Solutions; and Engineering. Its principal products include containment solutions, drug delivery systems, medical devices, diagnostic, analytical services, visual inspection machines, assembling and packaging machines, and glass forming machines. The company was founded in 1949 and is headquartered in Piombino Dese, Italy. Stevanato Group S.p.A. is a subsidiary of Stevanato Holding S.R.L.Shockwave Medical NASDAQ:SWAVShockwave Medical, Inc., a medical device company, develops and commercializes intravascular lithotripsy (IVL) technology for the treatment of calcified plaque in patients with peripheral and coronary vascular, and heart valve diseases in the United States and internationally. The company offers products for the treatment of peripheral artery disease (PAD), including M5 IVL catheter and M5+ IVL catheter, which are five-emitter catheters used in IVL system in medium-diameter vessels; S4 IVL catheter, a four-emitter catheter for use in IVL system in small-diameter vessels; and L6 IVL catheter, a six-emitter catheter used for IVL System in large diameter vessels. It also provides product for the treatment of coronary artery disease, such as C2 IVL catheter and C2+IVL catheter that are two-emitter catheters for use in IVL system; and Reducer, a device to treat refractory angina. In addition, the company develops COSIRA-II trial; shockwave C2 Aero, a coronary IVL catheter; shockwave javelin coronary, a non-balloon-based catheter platform to treat of tight, difficult-to-cross coronary lesions; shockwave L6; shockwave E8 catheter, to target long peripheral artery lesions; shockwave javelin peripheral, a non-balloon-based catheter platform, to treat tight, difficult-to-cross peripheral lesions. Further, it offers shockwave carotid IVL, a purpose-built IVL System to treat calcified carotid artery lesions; and Shockwave Crescendo, a platform developed to treat calcified, stenotic heart valves. It serves interventional cardiologists, vascular surgeons, and interventional radiologists through sales representatives and managers, and distributors. The company was incorporated in 2009 and is headquartered in Santa Clara, California. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Amazon's Prime Day Pullback Meets Bullish Golden Cross Signal Is Fortinet Ready to Break Out After Months of Consolidation? AST SpaceMobile: Is Market Noise Drowning Out a $100M Signal? CoreWeave's $9 Billion Power Play for Core Scientific Taiwan Semiconductor May Profit from Chinese Manufacturing Issues Micron Insiders Sell But Investors Should Buy, Buy, Buy Believe the Hype? Can SoFi Maintain Its 3-Month Rally? Sizzling Insider Buys for Your High-Yield Watchlist Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
